Latest Biopharmaceuticals News

Page 11 of 11

Paradigm Biopharma Boosts Cash by $6.3M to Power Osteoarthritis Trial

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Victor Sage

24 Jan 2025

Top